Bernard De Bruyne.

Bernard De Bruyne, M.D., Ph.D., Nico H.J. Pijls, M.D., Ph.D., Bindu Kalesan, M.P.H., Emanuele Barbato, M.D., Ph.D., Pim A.L. Tonino, M.D., Ph.D., Zsolt Piroth, M.D., Nikola Jagic, M.D.D., Gilles Rioufol, M.D., Ph.D., Nils Witt, M.D., Ph.D., Petr Kala, M.D., Philip MacCarthy, M.D.D., Keith G. Oldroyd, M.D., Kreton Mavromatis, M.D., Ganesh Manoharan, M.D., Peter Verlee, M.D., Ole Frobert, M.D., Nick Curzen, B.M., Ph.D., Jane B. Johnson, R.N., B.S.N.D., and William F. Fearon, M.D.1 In contrast, for the treatment of patients with steady coronary artery disease, controversy persists regarding the extent of the power from PCI, as compared with the best obtainable medical therapy, as a short management strategy.2-5 The potential benefit of revascularization depends upon the extent and presence of myocardial ischemia.6-8 Performing PCI on nonischemic stenoses isn’t beneficial9 and is probably harmful.10 Thus, careful selection of ischemia-inducing stenoses is vital for deriving the best reap the benefits of revascularization in patients with steady coronary artery disease.11-14 The usefulness of FFR-guided PCI as compared with PCI guided by angiography alone is supported by robust clinical outcome data.9,10,14-17 The aim of this trial was to determine whether FFR-guided PCI with drug-eluting stents in addition to the best available medical therapy is superior to the very best available medical therapy alone in reducing the rate of death, myocardial infarction, or unplanned hospitalization leading to urgent revascularization among patients with stable coronary artery disease.e., involving the consecutive enrollment of most eligible patients with stable coronary artery disease).The effect of ivacaftor as compared with placebo was significant in each subgroup that was analyzed . At week 48, a complete of 67 percent of subjects in the ivacaftor group, in comparison with 41 percent in the placebo group, were free from pulmonary exacerbations, corresponding to a hazard ratio with ivacaftor of 0.455 , or a 55 percent decrease in the chance of pulmonary exacerbation . There were 99 exacerbations in the placebo group, in comparison with 47 exacerbations in the ivacaftor group.